"Monoterpenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a core of 10 carbons generally formed via the mevalonate pathway from the combination of 3,3-dimethylallyl pyrophosphate and isopentenyl pyrophosphate. They are cyclized and oxidized in a variety of ways. Due to the low molecular weight many of them exist in the form of essential oils (OILS, VOLATILE).
| Descriptor ID |
D039821
|
| MeSH Number(s) |
D02.455.849.575
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Monoterpenes".
Below are MeSH descriptors whose meaning is more specific than "Monoterpenes".
This graph shows the total number of publications written about "Monoterpenes" by people in this website by year, and whether "Monoterpenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Monoterpenes" by people in Profiles.
-
miR-18a Inhibits BMP4 and HIF-1a Normalizing Brain Arteriovenous Malformations. Circ Res. 2020 10 09; 127(9):e210-e231.
-
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther. 2016 04; 15(4):618-27.
-
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood. 2012 Mar 15; 119(11):2568-78.
-
Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol. 2011 May 16; 24(5):744-51.
-
Components of lemon essential oil attenuate dementia induced by scopolamine. Nutr Neurosci. 2009 Apr; 12(2):57-64.
-
Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. Pharm Res. 2006 Dec; 23(12):2768-80.
-
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res. 2004 Nov 15; 10(22):7583-91.
-
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol. 2004 Oct; 54(4):368-76.
-
Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol. 2003 Nov; 52(5):361-6.
-
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs. 2003 Aug; 21(3):367-72.